Please assess the completion status of the following clinical trial:

Trial Title: T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of T1DM within \>3 and \<24 months of screening according to the American Diabetes Association criteria~* Between 18 and 45 years of age~* Positive test for Epstein-Barr antibody~* Positive test for at least one of the following antibodies:~  * ICA512-antibody~ * ICA~ * GAD65-antibody~ * Insulin (if assessed within 10 days of the onset of insulin therapy)~ * ZnT8~* Peak C-peptide \>0.1 pmol/ml (\>0.3 ng/ml) during MMTT challenge~* Adequate venous access to support draw of 400 ml whole blood and infusion of investigational therapy~Exclusion Criteria:~* Hemoglobin \<10.0 g/dL; leukocytes \<3,000/µL; neutrophils \<1,500/µL; lymphocytes \<800/µL; platelets \<100,000/µL~* Regulatory T cells present in peripheral blood at \<10 per µl as determined by flow cytometry~* Serologic evidence of HIV-1 or HIV-2 infection~* Evidence of current hepatitis B as demonstrated by HBsAg or circulating hepatitis B genomes~* Serologic evidence of hepatitis C infection~* Detectable circulating EBV or CMV genomes or active infection~* Positive PPD skin test defined as greater than or equal to 10 mm induration~* Chronic use of systemic glucocorticoids or other immunosuppressive agents, or biologic immunomodulators within 6 months prior to study entry. Specifically, subjects who have received over 7 days of treatment with 7.5mg of prednisone (or the equivalent) within 6 months prior to study entry will be excluded.~* History of malignancy ( including squamous cell carcinoma of the skin or cervix) except adequately treated basal cell carcinoma~* Any chronic illness or prior treatment which in the opinion of the investigator should preclude participation in the trial~* Pregnant or breastfeeding women, any female who is unwilling to use a reliable and effective form of contraception for 2 years afer Treg dosing and any male who is unwilling to use a reliable and effective form of contraception for 3 months after Treg dosing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Polyclonal Regulatory T Cells (Type: EXPERIMENTAL): Patients with Type 1 Diabetes Mellitus will have their regulatory T cells (Tregs) isolated by researchers and receive Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells by infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).